Pharmacovigilance signals mining for the glucagon-like peptide1 receptor agonists related psychiatric disorders based on the FDA adverse event reporting system(FAERS)
Objective Pharmacovigilance signals for glucagon-like peptide 1(GLP-1)receptor agonists related psychiatric disorders were mined using FDA adverse event reporting system(FAERS).Methods Adverse drug events(ADEs)reports from January 2010 to March 2023 were screened,and ADEs reports from patients taking six GLP-1 receptor agonists such as Exenatide,Lixisenatide,Liraglutide,Albiglutide,Dulaglutide,and Semaglutide were selected.Psychiatric signals were analyzed using the reporting odds ratio by disproportionality mearsure and false discovery rate correction was conducted.Results There were no positive signals with the six GLP-1 receptor agonists,but positive signals for preferred terms(PT)were found,including:nervousness,reduced frustration tolerance,fear of injection,bulimia,sleep disorder caused by general diseases,and insomnia caused by general diseases.Conclusion Positive signals of PT in GLP-1 receptor agonist related psychiatric disorders may be associated with the therapeutic effect of the drug and the patient's disease.
PharmacovigilanceGlucagon-like peptide 1 receptor agonistsPsychiatric disordersAdverse drug events
万方数据
维普
